What You Should Know:
– Atropos Health, the pioneer in translating real-world clinical data into high-quality personalized real-world evidence for care, today announced a $33 million Series B on the heels of the adoption of its Generative AI platform (GENEVA OSTM) by healthcare institutions, data platforms, research institutions, Life Sciences companies and more.
– The funding was led by Valtruis, with participation from new strategic investors including Cencora Ventures, McKesson Ventures, and Merck GHI Fund, along with existing investors Breyer Capital, Emerson Collective, and Presidio Ventures.
Atropos Health: Pioneering Real-World Evidence and AI Innovations in Healthcare
Founded in 2019 as a spin-out of Stanford University’s “Green Button” technology, Atropos Health was established by Brigham Hyde Ph.D., Nigam Shah MBBS, Ph.D., and Saurabh Gombar M.D., Ph.D., who are leaders in AI applications and Real-world Evidence Research in Healthcare. Their mission is to democratize access to high-quality real-world evidence to enhance decision-making and healthcare outcomes. Since its inception, Atropos Health has become a pioneer in generative AI, offering unique user experiences like ChatRWDTM, which dramatically reduces the time required to produce high-quality publication-grade real-world evidence from months to minutes through a chat-based AI co-pilot.
With new funding, Atropos Health aims to strengthen its position in value-based care. The company’s suite of evidence-generating applications supports whole-person care and value-based performance, already utilized by partners such as Arcadia. Atropos Health enables healthcare organizations to accelerate appropriate clinical decision-making, promoting high-value, low-cost care tailored to patients’ unique physiology. To advance this mission, the company is welcoming value-based care expert Mike Spadafore to its board.
As part of this funding round, Atropos Health will form strategic partnerships with life sciences and vertically integrated healthcare entities. Through a collaboration with Cencora, a leading global pharmaceutical solutions organization, Atropos Health will extend its real-world evidence platform to oncology and specialty care. In the fast-evolving field of Oncology, where patient outcomes are critical, oncologists and researchers can now utilize the Atropos Evidence Network, comprising millions of anonymized patient records converted into high-quality evidence, to inform their decisions. Pharmaceutical clients, including Janssen Research & Development, LLC (a Johnson & Johnson company), can leverage this evidence network to drive crucial R&D initiatives and expedite the development of new treatments.
Launched in Beta in Q4 of 2023, ChatRWD transforms the production of high-quality real-world evidence, reducing the process from months to minutes through a user-friendly chat interface designed for clinical and research purposes. While the speed of ChatRWD is groundbreaking, Atropos Health prioritizes accuracy and transparency of results. Built on the GENEVA OS technology, ChatRWD is an LLM-independent framework that ensures LLM security and integrity, eliminating the risk of hallucinations unacceptable in clinical evidence. An upcoming publication will detail this approach and its benefits for generating accurate evidence. Investment from this funding round will support the full launch of ChatRWD, with the potential to democratize access to high-quality, accurate, transparent, and personalized Real-World Evidence.
Atropos Health, the developer of GENEVA OSTM, provides an operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations partner with Atropos Health to bridge evidence gaps from bench to bedside, enhancing individual patient outcomes with data-driven care and accelerating research that advances medical science.
“As excitement over the application of Generative AI technology in healthcare turns from potential to practical applications, the focus of providers, life sciences, and other healthcare stakeholders turns to quality, transparency, and automation backed by tangible ROI. For decades, high-quality clinical evidence has served as the currency of value in healthcare. Atropos Health is built on investment in scaling the production of high quality, transparent, and now real-time evidence production that matches the standards of the clinical and research communities,” said Brigham Hyde, CEO and Co-Founder of Atropos Health. “This funding round, which includes multiple major strategic stakeholders in the healthcare ecosystem, is validation that our platform is rapidly becoming the standard not only for automation and user experience, but also as the trusted quality layer between healthcare data, and the critical evidence needed to better inform patient care, research, and policy.”
